Meta‐analysis: Post‐COVID‐19 functional dyspepsia and irritable bowel syndrome
Alimentary Pharmacology & Therapeutics · 2023-07 · 58 (1) · 6-15
DOI: 10.1111/apt.17513 ↗At a glance
Metaanalyse in Alimentary Pharmacology & Therapeutics, published online on 2023-04-10. Written by Giovanni Marasco and 5 co-authors. Institution: IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy. Major MEDLINE topics: Irritable Bowel Syndrome, Dyspepsia, COVID-19. Cited 51 times so far (Crossref); 50 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Università di Bologna, Fondazione del Monte di Bologna e Ravenna, Horizon 2020 Framework Programme.
Abstract (original language)
Introduction
The burden of post‐COVID‐19 functional dyspepsia (FD) and irritable bowel syndrome (IBS) remains unclear. The aim of this meta‐analysis was to estimate the rate of post‐COVID‐19 FD and IBS.
Methods
MEDLINE, Scopus and Embase were searched through 17 December 2022. Studies reporting the incidence of FD and/or IBS in COVID‐19 survivors and controls (without COVID‐19), when available, according to the Rome criteria, were included. Estimated incidence with 95% confidence intervals (CI) was pooled. The odds ratio (OR) with 95% confidence intervals (CI) was pooled; heterogeneity was expressed as I 2 .
Results
Ten studies met the inclusion criteria and were included in the analysis. Overall, four studies including 1199 COVID‐19 patients were considered for FD. Post‐COVID‐19 FD was reported by 72 patients (4%, 95% CI: 3%–5% and I 2 0%). The pooled OR for FD development (three studies) in post‐COVID‐19 patients compared to controls was 8.07 (95% CI: 0.84–77.87, p = 0.071 and I 2 = 67.9%). Overall, 10 studies including 2763 COVID‐19 patients were considered for IBS. Post‐COVID‐19 IBS was reported by 195 patients (12%, 95% CI: 8%–16%, I 2 95.6% and Egger's p = 0.002 test). The pooled OR for IBS development (four studies) in COVID‐19 patients compared to controls was 6.27 (95% CI: 0.88–44.76, p = 0.067 and I 2 = 81.4%); considering only studies with a prospective COVID‐19 cohort (three studies), the pooled OR was 12.92 (95% CI: 3.58–46.60, p < 0.001 and I 2 = 0%).
Conclusions
COVID‐19 survivors were found to be at risk for IBS development compared to controls. No definitive data are available for FD.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy.
- Department of Medical and Surgical Science, University of Bologna, Bologna, Italy.
- Gastroenterology and Endoscopy Unit, S. Elia - Raimondi Hospital, Caltanissetta, Italy.
ORCID profiles: Giovanni Marasco, Marcello Maida, Cesare Cremon, Maria Raffaella Barbaro, Giovanni Barbara
Funding
- Università di Bologna
- Fondazione del Monte di Bologna e Ravenna
- Horizon 2020 Framework Programme
Cite
APA
Marasco, G., Maida, M., Cremon, C., Barbaro, M. R., Stanghellini, V., & Barbara, G. (2023). Meta‐analysis: Post‐COVID‐19 functional dyspepsia and irritable bowel syndrome. Alimentary Pharmacology & Therapeutics, 58(1), 6-15. https://doi.org/10.1111/apt.17513
Vancouver
Marasco G, Maida M, Cremon C, Barbaro MR, Stanghellini V, Barbara G. Meta‐analysis: Post‐COVID‐19 functional dyspepsia and irritable bowel syndrome. Alimentary Pharmacology & Therapeutics. 2023;58(1):6-15. doi:10.1111/apt.17513
BibTeX
@article{Marasco2023,
author = {Marasco, Giovanni and Maida, Marcello and Cremon, Cesare and Barbaro, Maria Raffaella and Stanghellini, Vincenzo and Barbara, Giovanni},
title = {Meta‐analysis: Post‐COVID‐19 functional dyspepsia and irritable bowel syndrome},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2023},
volume = {58},
number = {1},
pages = {6--15},
doi = {10.1111/apt.17513}
}
EUVIMED